Recombinant Mouse Semaphorin 5A Fc Chimera Protein, CF

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse Semaphorin 5A Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by the ability of the immobilized protein to support the adhesion of human pancreatic cancer cells. The ED₅₀ for this effect is 0.9-3.6 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived mouse Semaphorin 5A protein
  

  Mouse Semaphorin 5A (Met1 - Thr765) Accession # NP_033180	IEGRMDP	Mouse IgG2A (Glu98 - Lys330)
  N-terminus		C-terminus

• Accession #: NP_033180
• N-terminal Sequence: Glu23
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: Sema5a
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 110.8 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 120-140 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse Semaphorin 5A Fc Chimera Protein, CF

• FLJ12815
• sema domain, seven thrombospondin repeats (type 1 and type 1-like)
• Sema F
• SEMA5A
• SEMAF
• Semaphorin 5A
• semaphorin F
• semaphorin-5A
• Semaphorin-F
• semF
• transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A

Background

Semaphorin 5A (Sema5A, previously called SemaF) is a 140 kDa protein of the semaphorin family of axon guidance molecules (1 ‑ 4). Class 5 semaphorins are type I transmembrane glycoproteins with an N-terminal Sema domain and multiple juxtamembrane type 1 thrombospondin (TSP) repeats within their extracellular domains (1 ‑ 3). Sema5A is expressed developmentally in oligodendrocytes, neuroepithelial cells surrounding retinal axons, the base of limb buds, the cardiac atrial septum and endocardial cushions, and the mesoderm surrounding cranial vessels (3 ‑ 6). The mouse Sema5A cDNA encodes a 22 amino acid (aa) signal sequence, a 946 aa extracellular domain (ECD), a 24 aa transmembrane sequence and an 85 aa cytoplasmic portion. Within aa 23 ‑ 765, which includes the sema domain and four of the seven TSP repeats, mouse Sema5A shares 93%, 98%, 93%, 92% and 91% aa identity with corresponding human, rat, porcine, bovine and canine sequences. Semaphorins typically transduce signals through transmembrane plexins (1, 2). The sema domain of Sema5A binds plexin B3, triggering signaling via HGF R/c-Met (7). Both Sema5A and plexin B3 are expressed postnatally during differentiation and migration of central nervous system oligodendrocytes. However, plexin B3 is not significantly expressed prenatally and therefore unlikely to be the Sema5A receptor during development (7, 8). The Sema5A TSP repeats interact with either heparin sulfate or chondroitin sulfate proteoglycans (HSPG, CSPG) (9). HSPG interaction promotes attraction, while CSPG interaction promotes repulsion and is essential for axon fasciculation, independent of plexin B3 (9, 10). Sema5A mutations have been implicated in the human genetic syndrome, cri-du-chat, while some polymorphisms may increase risk for neurodegenerative diseases such as Parkinson’s (11, 12). Sema5A expression may be up‑regulated in metastatic cancer cells and down‑regulated in autism (13, 14). High expression of Sema5A has been associated with tumor growth and metastasis in pancreatic cancer (15).

1. Flannery, E. and M. Duman-Scheel (2009) Curr. Drug Targets 10:611.
2. Zhou, Y. et al. (2008) Trends Biol. Sci. 33:161.
3. Adams, R.H. et al. (1996) Mech. Dev. 57:33.
4. Oster, S.F. et al. (2003) Development 130:775.
5. Goldberg, J.L. et al. (2004) J. Neurosci. 24:4989.
6. Fiore, R. et al. (2005) Mol. Cell. Biol. 25:2310.
7. Artigiani, S. et al. (2004) EMBO Rep. 5:710.
8. Worzfeld, T. et al. (2004) Eur. J. Neurosci. 19:2622.
9. Kantor, D.B. et al. (2004) Neuron 44:961.
10. Hilario, J.D. et al. (2008) Dev. Biol. 326:190.
11. Simmons, A.D. et al. (1998) Biochem. Biophys. Res. Commun. 242:685.
12. Lin, L. et al. (2009) Trends Neurosci. 32:142.
13. Pan, G-Q. et al. (2009) World J. Gastroenterol. 15:2800.
14. Melin, M. et al. (2006) Neuropsychobiology 54:64.
15. Sadanandam A. et al. (2010) Int J. Cancer 127(6)1373.

Bioinformatics

• Gene Symbol: Sema5a
• Uniprot:
  • NP_033180()